haloperidol has been researched along with Adverse Drug Event in 28 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "To evaluate the therapeutic efficacy and tolerability of flunarizine compared to haloperidol in outpatients with stable and chronic DSM-IV-defined schizophrenia and schizoaffective disorder." | 9.13 | Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ( Bisol, LW; Borba, DL; Bressan, RA; Brunstein, MG; Daltio, CS; de Oliveira, RV; de Souza, SE; Lara, DR; Ottoni, GL; Paz, GE; Ramos, FL, 2008) |
| "To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol." | 9.01 | Haloperidol discontinuation for people with schizophrenia. ( AbouDamaah, A; Aboudamaah, S; AlMounayer, N; Diaa Aldeen, MR; Essali, A; Marwa, ME; Turkmani, K, 2019) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "Agitated delirium is common in patients undergoing mechanical ventilation, and is often treated with haloperidol despite concerns about safety and efficacy." | 5.14 | Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. ( Ainslie, WR; Bates, S; Bellomo, R; Goldsmith, D; O'Sullivan, K; Reade, MC, 2009) |
| "To evaluate the therapeutic efficacy and tolerability of flunarizine compared to haloperidol in outpatients with stable and chronic DSM-IV-defined schizophrenia and schizoaffective disorder." | 5.13 | Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. ( Bisol, LW; Borba, DL; Bressan, RA; Brunstein, MG; Daltio, CS; de Oliveira, RV; de Souza, SE; Lara, DR; Ottoni, GL; Paz, GE; Ramos, FL, 2008) |
| "To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol." | 5.01 | Haloperidol discontinuation for people with schizophrenia. ( AbouDamaah, A; Aboudamaah, S; AlMounayer, N; Diaa Aldeen, MR; Essali, A; Marwa, ME; Turkmani, K, 2019) |
| " In order to assess the validity and the robustness of the approach, we elaborated on two important case studies, namely, clozapine-induced cardiomyopathy/myocarditis versus haloperidol-induced cardiomyopathy/myocarditis, and apixaban-induced cerebral hemorrhage." | 3.85 | Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. ( Jaulent, MC; Koutkias, VG; Lillo-Le Louët, A, 2017) |
| " Sample size was reduced from 311 to 156 patients, thereby decreasing the number of patients exposed to placebo from 54 to 30 and the number exposed to the active control with a known side effect from 126 to 60." | 2.74 | Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. ( Baker, R; Breier, A; Dunayevich, E; Lindborg, S; Seaman, J; Spann, M, 2009) |
| "Delirium is an acute disturbance in attention, cognition, and awareness that fluctuates over time." | 1.91 | Delirium in Older Persons: Prevention, Evaluation, and Management. ( Chin, E; Jaqua, EE; Nguyen, VTN, 2023) |
| "Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials." | 1.72 | Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. ( Byeon, SJ; Chung, SJ; Oh, S, 2022) |
| " A disproportionality analysis was performed to detect a signal for reporting "infective-pneumonia" and "pneumonia-aspiration" and antipsychotics using reports submitted between 2004 and 2019 to the FDA adverse events spontaneous reporting system (FAERS) database." | 1.62 | Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. ( Cepaityte, D; Egberts, T; Kouvelas, D; Leucht, S; Papazisis, G; Siafis, S, 2021) |
| "Haloperidol is an efficacious antipsychotic drug that has serious, unpredictable motor side effects that limit its utility and cause noncompliance in many patients." | 1.40 | Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis. ( Adkins, DE; Barrick, CJ; Crowley, JJ; de Villena, FP; Kim, Y; Lenarcic, AB; Miller, DR; Quackenbush, CR; Shaw, GS; Sullivan, PF; Valdar, W, 2014) |
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| " There was a dose-response relation for all drugs except quetiapine." | 1.38 | Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. ( Avorn, J; Crystal, S; Gerhard, T; Huybrechts, KF; Levin, R; Lucas, JA; Olfson, M; Schneeweiss, S, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.86) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Oh, S | 1 |
| Byeon, SJ | 1 |
| Chung, SJ | 1 |
| McClarty, BM | 1 |
| Chakraborty, S | 1 |
| Rodriguez, G | 1 |
| Dong, H | 1 |
| Jaqua, EE | 1 |
| Nguyen, VTN | 1 |
| Chin, E | 1 |
| Moskowitz, A | 1 |
| Andersen, LW | 1 |
| Holmberg, MJ | 1 |
| Grossestreuer, AV | 1 |
| Berg, KM | 1 |
| Granfeldt, A | 1 |
| Cepaityte, D | 1 |
| Siafis, S | 1 |
| Egberts, T | 1 |
| Leucht, S | 1 |
| Kouvelas, D | 1 |
| Papazisis, G | 1 |
| Essali, A | 1 |
| Turkmani, K | 1 |
| Aboudamaah, S | 1 |
| AbouDamaah, A | 1 |
| Diaa Aldeen, MR | 1 |
| Marwa, ME | 1 |
| AlMounayer, N | 1 |
| Crowley, JJ | 1 |
| Kim, Y | 1 |
| Lenarcic, AB | 1 |
| Quackenbush, CR | 1 |
| Barrick, CJ | 1 |
| Adkins, DE | 1 |
| Shaw, GS | 1 |
| Miller, DR | 1 |
| de Villena, FP | 1 |
| Sullivan, PF | 1 |
| Valdar, W | 1 |
| Warnier, MJ | 1 |
| Rutten, FH | 1 |
| Souverein, PC | 1 |
| de Boer, A | 1 |
| Hoes, AW | 1 |
| De Bruin, ML | 1 |
| Koutkias, VG | 1 |
| Lillo-Le Louët, A | 1 |
| Jaulent, MC | 1 |
| Spann, M | 1 |
| Lindborg, S | 1 |
| Seaman, J | 1 |
| Baker, R | 1 |
| Dunayevich, E | 1 |
| Breier, A | 1 |
| Bisol, LW | 1 |
| Brunstein, MG | 1 |
| Ottoni, GL | 1 |
| Ramos, FL | 1 |
| Borba, DL | 1 |
| Daltio, CS | 1 |
| de Oliveira, RV | 1 |
| Paz, GE | 1 |
| de Souza, SE | 1 |
| Bressan, RA | 1 |
| Lara, DR | 1 |
| Reade, MC | 1 |
| O'Sullivan, K | 1 |
| Bates, S | 1 |
| Goldsmith, D | 1 |
| Ainslie, WR | 1 |
| Bellomo, R | 1 |
| Meyer-Massetti, C | 1 |
| Cheng, CM | 1 |
| Sharpe, BA | 1 |
| Meier, CR | 1 |
| Guglielmo, BJ | 1 |
| Kane, JM | 1 |
| Potkin, SG | 1 |
| Daniel, DG | 1 |
| Buckley, PF | 1 |
| Huybrechts, KF | 1 |
| Gerhard, T | 1 |
| Crystal, S | 1 |
| Olfson, M | 1 |
| Avorn, J | 1 |
| Levin, R | 1 |
| Lucas, JA | 1 |
| Schneeweiss, S | 1 |
| Preskorn, SH | 1 |
| Kruesi, M | 1 |
| van Schiak, J | 1 |
| Bryant, SG | 1 |
| Cherin, P | 1 |
| Colvez, A | 1 |
| Deville de Periere, G | 1 |
| Sereni, D | 1 |
| Zisook, S | 1 |
| Braff, DL | 1 |
| Chase, TN | 1 |
| Lien, EJ | 1 |
| Gudauskas, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is Flunarizine a Cheap, Well-Tolerated and Long-Acting Atypical Antipsychotic? A Randomized Double-Blind Flexible-Dose Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia[NCT00740259] | Phase 4 | 70 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium[NCT00505804] | Phase 2 | 20 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effect of Clonidine vs. Dexmedetomidine in Addition to Standard Treatment in Agitated Delirium in Intensive Care Patients: Pilot Study.[NCT04758936] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for haloperidol and Adverse Drug Event
| Article | Year |
|---|---|
Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review.
Topics: Adrenal Cortex Hormones; Antipsychotic Agents; Critical Illness; Dexmedetomidine; Drug-Related Side | 2020 |
Haloperidol discontinuation for people with schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; R | 2019 |
The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Drug-Related Side Effects and A | 2010 |
Drug-induced extrapyramidal disorders.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Benztropine; Dihydroxyphenylalanine; Dopa | 1972 |
4 trials available for haloperidol and Adverse Drug Event
| Article | Year |
|---|---|
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Double-Blind Method; Drug-Related Side Effects | 2009 |
Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Analysis of Variance; Antipsychotic Agents; Dopamine Antagonists; Doubl | 2008 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial.
Topics: Adult; Aged; Delirium; Dexmedetomidine; Dopamine Antagonists; Drug-Related Side Effects and Adverse | 2009 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
20 other studies available for haloperidol and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cl | 2022 |
Histone deacetylase 1 regulates haloperidol-induced motor side effects in aged mice.
Topics: Animals; Antipsychotic Agents; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Histone | 2023 |
Delirium in Older Persons: Prevention, Evaluation, and Management.
Topics: Aged; Cognition; Delirium; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Inp | 2023 |
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antipsychotic A | 2021 |
Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis.
Topics: Animals; Antipsychotic Agents; Bayes Theorem; Brain; Dopamine Antagonists; Drug Monitoring; Drug-Rel | 2014 |
Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Monitoring; Drug Prescriptions; Drug-Related Side E | 2015 |
Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Cardiotoxicity; Cerebral Hemorrhage; | 2017 |
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cause of Death; Comorbidity; Dementia; Dibenzothiazep | 2012 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; | 2008 |
Illicit haldol.
Topics: Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Illicit Drugs | 1981 |
Street drug misrepresentation.
Topics: Adult; Diazepam; Drug-Related Side Effects and Adverse Reactions; Dystonia; Haloperidol; Humans; Ill | 1980 |
Risk of syncope in the elderly and consumption of drugs: a case-control study.
Topics: Acepromazine; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antiparkinson Agent | 1997 |
Delirium: recognition and management in the older patient.
Topics: Aged; Aging; Anti-Anxiety Agents; Benzodiazepines; Delirium; Diagnosis, Differential; Drug-Related S | 1986 |
Structure side-effect sorting of drugs. I. Extrapyramidal syndrome.
Topics: Anticonvulsants; Basal Ganglia Diseases; Benzamides; Computers; Diazepam; Drug-Related Side Effects | 1973 |